Radbio

RADBIO is a biotech company focused on early-stage drug development. Based on the discovery of a new human protein, we're developing a new drug called Brecept for treating autoimmune and fibrotic diseases.Brecept has shown efficacy in animal models of skin and lung fibrosis (in the context of systemic sclerosis, our lead indication), liver fibrosis, wound healing, and solid colorectal and breast cancer tumors. It has also shown anti-aging potential, opening the door to a new development track in cosmetics.We're currently advancing CMC development, the regulatory phase required for FDA approval to begin clinical phases — a key milestone in developing a biologic drug.